title: Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.
abstract: BACKGROUND
  Several studies have suggested that bisphosphonates have an antitumor effect. In the current study, the authors sought to evaluate whether the use of bisphosphonates increased the rate of pathological complete response (pCR) in patients with breast cancer.
  
  
  METHODS
  The authors identified 1449 patients with breast cancer who were receiving taxane- and anthracycline-based neoadjuvant chemotherapy between 1995 and 2007 at The University of Texas MD Anderson Cancer Center. Patients who received bisphosphonates for osteopenia or osteoporosis while receiving chemotherapy were also identified. The primary outcome was the percentage of patients achieving a pCR. Groups were compared using the chi-square test. A multivariable logistic regression model was fit to examine the relation between the use of bisphosphonates and pCR. An exploratory survival analysis using the Kaplan-Meier method was performed; groups were compared using the log-rank test.
  
  
  RESULTS
  Of the 1449 patients included, 39 (2.7%) received bisphosphonates. Those receiving bisphosphonates were older (P < .001) and less likely to be obese (P = .04). The pCR rate was 25.4% in the bisphosphonate group and 16% in the nonbisphosphonate group (P = .11). In the multivariable model, patients treated with bisphosphonates tended to have higher rates of pCR (odds ratio, 2.18; 95% confidence interval, 0.90-5.24); however, the difference was not found to be statistically significant. With a median follow-up of 55 months (range, 3 months-145 months), no differences in disease recurrence or survival were observed.
  
  
  CONCLUSIONS
  The use of bisphosphonates at the time of neoadjuvant chemotherapy was not found to be associated with a statistically significant increase in the rates of pCR. The observed estimates suggest a positive effect; however, the small percentage of patients receiving bisphosphonates likely affected the power to detect a statistically significant difference.
authors: Divison of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.
authors: Mariana
authors: M
authors: Chavez-Macgregor
authors: Erika
authors: E
authors: Brown
authors: Xiudong
authors: X
authors: Lei
authors: Jennifer
authors: J
authors: Litton
authors: Funda
authors: F
authors: Meric-Bernstram
authors: Elizabeth
authors: E
authors: Mettendorf
authors: Leonel
authors: L
authors: Hernandez
authors: Vicente
authors: V
authors: Valero
authors: Gabriel N
authors: GN
authors: Hortobagyi
authors: Ana Maria
authors: AM
authors: Gonzalez-Angulo
references: J Am Coll Surg. 1995 Mar;180(3):297-306
references: 7874340
references: J Clin Oncol. 1999 Feb;17(2):460-9
references: 10080586
references: J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78
references: 18695136
references: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jul;106(1):5-13
references: 18504149
references: J Clin Oncol. 1998 Aug;16(8):2672-85
references: 9704717
references: J Clin Oncol. 2010 Aug 1;28(22):3577-81
references: 20567021
references: J Clin Oncol. 2010 Aug 1;28(22):3582-90
references: 20567009
references: J Clin Oncol. 2007 Oct 1;25(28):4414-22
references: 17785706
references: N Engl J Med. 1998 Aug 6;339(6):357-63
references: 9691101
references: Clin Breast Cancer. 2005 Jun;6(2):163-8
references: 16001995
references: J Natl Compr Canc Netw. 2010 Mar;8(3):279-86
references: 20202461
references: Int J Cancer. 2010 Jan 15;126(2):522-32
references: 19621384
references: Oncologist. 2004;9 Suppl 4:14-27
references: 15459426
references: Surg Clin North Am. 2003 Aug;83(4):803-19
references: 12875597
references: Br J Cancer. 2010 Mar 30;102(7):1099-105
references: 20234364
references: Clin Cancer Res. 2004 Oct 1;10(19):6622-8
references: 15475452
references: N Engl J Med. 2009 Feb 12;360(7):679-91
references: 19213681
references: Cancer Res. 1986 May;46(5):2578-81
references: 3697997
references: J Clin Oncol. 2002 Aug 1;20(15):3219-24
references: 12149294
references: Surg Gynecol Obstet. 1957 Jul;105(1):97-102
references: 13442910
references: Am J Clin Pathol. 1982 Dec;78(6):806-16
references: 7148748
references: J Natl Cancer Inst Monogr. 2001;(30):96-102
references: 11773300
references: Lancet Oncol. 2010 May;11(5):421-8
references: 20362507
references: Clin Cancer Res. 2003 Jan;9(1):124-33
references: 12538460
references: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474
references: 16034900
references: Prostate. 2004 May 1;59(2):120-31
references: 15042612
references: J Clin Oncol. 2001 Jan 1;19(1):10-7
references: 11134190